Background: The treatment landscape of metastatic hormone receptor (HR) positive breast cancer has been changed in recent years. Availability of CDK 4/6 inhibitor and other hormone therapy has changed the treatment algorithm for these patient, we retrospectively analyzed our metastatic HR positive breast cancer patients.
Materials and Methods: In this study, we retrospectively analyzed the case records of hr positive metastatic breast cancer patient treated at department of medical oncology from October 2016 to September 2018. Demographical characteristics, site of metastasis, objective response and clinical benefit response and toxicity profile were analyzed.
Results: We treated a total of 178 patients of MBC with HT at our center during the study period. One hundred fifty-two patients received HT alone (control group) and 26 patients received HT and CDK 4/6 inhibitor (study group). The median age of patients was 56 and 58 years in the control group and study group. The ORR was 41.7 versus 57.9 (95% CI [1.01–2.56]), and the CBR was 66.1% versus 78.9%; (CI [1.18–3.56]) (P < 0.05) of the patients in control and study groups, respectively.
Conclusions: Among patients with HR-positive, advanced breast cancer, hormone therapy is efficacious addition of CDK 4/6 inhibitor improve the efficacy with tolerable side effects.


中文翻译：

---

CDK 4/6 时代的转移性激素受体阳性乳腺癌：结果审核


背景：近年来，转移性激素受体（HR）阳性乳腺癌的治疗前景发生了变化。CDK 4/6 抑制剂和其他激素疗法的可用性改变了这些患者的治疗方案，我们回顾性分析了我们的转移性 HR 阳性乳腺癌患者。
材料与方法：在本研究中，我们回顾性分析了 2016 年 10 月至 2018 年 9 月在肿瘤内科治疗的 hr 阳性转移性乳腺癌患者的病例记录。人口学特征、转移部位、客观反应和临床获益反应和毒性概况进行了分析。
结果：在研究期间，我们在我们的中心共治疗了 178 名 MBC 患者。152 名患者单独接受 HT（对照组），26 名患者接受 HT 和 CDK 4/6 抑制剂（研究组）。对照组和研究组患者的中位年龄分别为 56 岁和 58 岁。ORR 为 41.7 对 57.9（95% CI [1.01–2.56]），CBR 为 66.1% 对 78.9%；(CI [1.18–3.56]) (P < 0.05) 分别是对照组和研究组的患者。
结论：在 HR 阳性的晚期乳腺癌患者中，激素治疗是有效的，加用 CDK 4/6 抑制剂可提高疗效，且副作用可耐受。